Developer docs
API playgroundTry for free, no card

Search company profiles

Genomic Expression

Full company profile

uuid0003tci

Namestring
Genomic Expression
Legal namestring
Genomic Expression
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Genomic Expression operates the OneRNA® Platform, a quantitative CLIA-validated whole-transcriptome RNA sequencing system that analyzes approximately 20,000 mRNAs from real clinical samples including archival FFPE, CTCs, and liquid biopsies (blood, saliva, urine). The platform's proprietary sample preparation technology, invented by CSO and co-founder Morten Pedersen, enables RNA-seq in samples where RNA is typically destroyed. Patient RNA profiles are compared against a curated true-normal tissue database to statistically power diagnostic conclusions, and a curated drug-target-ligand database connects abnormally expressed genes to approved treatments and clinical trials. The company reports a diagnostic yield of close to 100% in matching patients to approved drugs, versus approximately 40% for DNA panels. The product surface has expanded with OneRNA® CDx AI, a companion diagnostics module that delivers an algorithm-based AI endpoint for pharma partners at a stated development cost of under $1M per program.

The company serves three customer segments: hospitals and healthcare systems (deploying OneRNA in their own CLIA labs with proprietary reagents, APIs, and HIPAA-compliant EMR integration under RNA-seq-specific payer codes); clinicians and oncologists (referring individual patient cases when standard treatment fails or cancer recurs); and pharmaceutical and biotech companies (target validation, companion diagnostics development, label expansion, and clinical study support, including rescue of failed drugs). Revenue mechanics span transaction-fee CLIA diagnostic testing, recurring hospital platform licensing, and professional services for pharma research and CDx development, with all pricing conducted on a quote-based, non-public basis. Distribution is direct and enterprise-led, with no channel or reseller model.

Genomic Expression is a privately held company headquartered in Beverly, Massachusetts, founded in 2009, with 1-10 employees. The company has raised approximately $6.5M cumulatively through grants from the Danish Innovation Fund, Horizon Europe, EuroStars, and the US National Cancer Institute, plus angel funding from Pipeline Angels and Harvard Business Angels, with additional disclosed rounds including a 2017 EISMEA grant and a 2018 financing. Management is led by CEO and co-founder Gitte Pedersen (former Novo Nordisk executive) alongside CSO Morten Pedersen and CMO Jesper Zeuthen (co-founder of GeneMap and Topotarget, both of which completed IPOs). The company is CLIA-validated, HIPAA-compliant, and has received recognition including Forbes feature, EIC Lifescience Award, MedTech Innovator Top 50, XTC Top 10, and XPRIZE Rapid Covid Testing semifinalist.

Short descriptiontext

Genomic Expression operates the OneRNA platform, a quantitative whole-transcriptome RNA sequencing system for cancer diagnostics that matches patients to approved drugs and clinical trials. It serves hospitals deploying the platform in-house, clinicians, and pharma companies developing companion diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBeverly, United States
HQ citystring
Beverly
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA sequencing diagnostics, companion diagnostics services, molecular diagnostics platform, clinical laboratory testing, transcriptome analysis services
Industry4 codes
PRIMARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1CLIA Diagnostic Testing Services
TypeTransaction Fee
Description

RNA-seq based cancer diagnostics performed in CLIA-certified lab, billed under RNA-seq-specific payer code. Revenue from diagnostic testing services matched to drugs and clinical trials.

genomicexpression.com
2Hospital Platform Licensing
TypeSubscription Recurring
Description

Hospitals implement OneRNA platform in their own CLIA labs using proprietary reagents and APIs, generating new revenue under RNA-seq payer codes.

genomicexpression.com
3Pharma Research Services
TypeProfessional Services
Description

Target validation, companion diagnostics development, and clinical study support services for biotech and pharma companies. CDx development under $1M with algorithm deliverables.

genomicexpression.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1OneRNA®
Description

A quantitative CLIA-validated whole-transcriptome RNA sequencing platform that analyzes all mRNAs to detect disease, match patients to drugs, and enable precision medicine in oncology.

genomicexpression.com
Core offering1 text field

Genomic Expression provides the OneRNA® Platform, a CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from real clinical samples (archival FFPE, CTCs, liquid biopsy) to detect disease and match oncology patients to approved drugs and clinical trials. The company commercializes this technology through three models: CLIA-certified diagnostic testing services reimbursed under RNA-seq-specific payer codes, licensing of the platform into hospital CLIA labs with proprietary reagents and APIs, and pharma research services for target validation, companion diagnostics development, and clinical study support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Close to 100% diagnostic yield matching patients to approved drugs (vs 40% for DNA panels, dropping to 26% in low mutation tumors)
+3 more records
Product overview1 text field

Genomic Expression offers a single unified platform, the OneRNA® Platform, augmented by a companion diagnostics module called OneRNA® CDx AI. The core OneRNA® Platform is a quantitative, CLIA-validated whole-transcriptome RNA-seq system that analyzes approximately 20,000 mRNAs from archival FFPE, CTCs, and liquid biopsy samples to match nearly all patients to approved drugs or clinical trials. The OneRNA® CDx AI module extends the platform by enabling pharmaceutical companies to derive companion diagnostics directly from whole-transcriptome data on an AI endpoint. Both offerings share the same underlying RNA-seq technology, sample types, and clinical validation infrastructure, with the CDx module representing a specialized application for drug development and label expansion.

Product and service4 records
1OneRNA® Platform
CategoryMolecular Diagnostics Core Platform
Description

Quantitative, CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from patient samples including archival FFPE, circulating tumor cells, and liquid biopsies (blood, saliva, urine) to detect disease, monitor health, and match cancer patients to approved drugs and clinical trials with close to 100% diagnostic yield. Compares patient RNA against a database of true normal tissue and connects abnormal gene expression to a curated drug-target-ligand database of approved treatments and clinical trials.

2CLIA-Certified RNA Diagnostic Testing Services
CategoryClinical Laboratory Services
Description

Diagnostic testing services performed in Genomic Expression's CLIA-certified laboratory using the OneRNA® Platform, billed under RNA-seq-specific payer codes and accepted by Medicare and select private payors. Delivers diagnostic reports matching patients to approved drugs and clinical trials.

3OneRNA Platform Deployment for Hospital CLIA Labs
CategoryHospital Platform Deployment Service
Description

Enterprise platform implementation service that installs the OneRNA® Platform in a hospital's own CLIA-certified laboratory, including proprietary reagents, APIs, and HIPAA-compliant EMR integration, enabling the hospital to run quantitative whole-transcriptome RNA diagnostics in-house and capture reimbursement under RNA-seq-specific payer codes.

4Pharma RNA Research & Companion Diagnostics Services
CategoryPharmaceutical Research and Companion Diagnostics Services
Description

Research and development services for biotech and pharmaceutical partners, covering target validation using whole-transcriptome RNA, companion diagnostic (CDx) development with algorithm deliverables under $1M, clinical study design and support, label expansion, and rescue of failed drug programs using real patient RNA data.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Foundation Medicine is the dominant DNA-based comprehensive genomic profiling provider for oncology, serving hospitals, oncologists, and pharma CDx partners. It is comparable because it sells tumor profiling into the same hospital and pharma channels, but it is anchored on DNA panel content where Genomic Expression's whole-transcriptome approach claims superior yield.

TypeBroad incumbent
Description

Guardant Health is a leading liquid-b biopsy and genomics company offering Guardant360 for tumor profiling and GuardantINFINITY for multi-omics including RNA. It is comparable because it serves oncology clinicians, hospitals, and pharma with tumor molecular profiling, with an increasing focus on RNA expression that overlaps with OneRNA's whole-transcriptome thesis.

TypeBroad incumbent
Description

Natera is a molecular diagnostics company offering cell-free DNA and RNA-based tests across oncology (Signatera for MRD) and reproductive health. It is comparable as a CLIA-certified molecular diagnostics operator with hospital and pharma channels, though anchored in cell-free DNA MRD rather than whole-transcriptome tumor profiling.

TypeDirect peer
Description

Personalis provides ImmunoID Next, a comprehensive tumor profiling platform combining whole-genome, exome, and RNA sequencing for oncology and immuno-oncology applications. Comparable as a direct competitor in whole-transcriptome tumor analysis serving pharma and clinical customers, with a similar emphasis on immune-therapy target and tumor microenvironment detection.

5Tempus AI
TypeBroad incumbent
Description

Tempus is a large-scale AI-powered precision medicine company offering multi-modal sequencing (DNA and RNA), clinical data, and analytics for oncology. It is broadly comparable as an oncology sequencing and data platform targeting hospitals, clinicians, and pharma, but operates at far greater scale and with DNA-first workflows that Genomic Expression's RNA-first platform aims to differentiate against.

TypeDirect peer
Description

Caris offers multi-omics tumor profiling including whole-transcriptome RNA sequencing (MI Profile) plus DNA and protein analysis for oncology. It is the closest direct peer because it provides RNA-based molecular profiling and companion diagnostics to clinicians, hospitals, and pharma on a CLIA-certified basis, directly competing for the same diagnostic yield narrative.

TypeBroad incumbent
Description

NeoGenomics is a clinical oncology laboratory offering comprehensive genomic profiling, including RNA fusion and expression assays, to hospitals and oncologists. It competes in the same hospital and CLIA diagnostic channel but with a much broader menu and footprint; relevant as an incumbent reference lab that Genomic Expression must displace or partner with.

TypeDirect peer
Description

Adaptive Biotechnologies applies immune repertoire sequencing (T-cell and B-cell receptor sequencing via RNA) to oncology minimal residual disease and immune profiling. Comparable as an RNA-sequencing-driven diagnostics company serving pharma and clinicians, though focused on immune receptor rather than whole-transcriptome tumor profiling.

TypeBroad incumbent
Description

Exact Sciences, recently acquired by Abbott for ~$20B per company materials, is a major molecular diagnostics franchise with oncology screening and profiling products. It illustrates the size and M&A appetite for sequencing-based cancer diagnostics and is broadly comparable as a large-scale oncology molecular diagnostics operator.

TypeBroad incumbent
Description

Veracyte is a genomic diagnostics company offering RNA-based and multi-omics tests in oncology (e.g., Afirma for thyroid, Decipher Prostate). It is comparable as an RNA-first diagnostics operator serving hospitals and clinicians, but focused on specific indications rather than whole-transcriptome pan-oncology profiling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genomic Expression

Molecular Diagnosticsgenomicexpression.com

Genomic Expression operates the OneRNA platform, a quantitative whole-transcriptome RNA sequencing system for cancer diagnostics that matches patients to approved drugs and clinical trials. It serves hospitals deploying the platform in-house, clinicians, and pharma companies developing companion diagnostics.

What Genomic Expression does

Genomic Expression operates the OneRNA® Platform, a quantitative CLIA-validated whole-transcriptome RNA sequencing system that analyzes approximately 20,000 mRNAs from real clinical samples including archival FFPE, CTCs, and liquid biopsies (blood, saliva, urine). The platform's proprietary sample preparation technology, invented by CSO and co-founder Morten Pedersen, enables RNA-seq in samples where RNA is typically destroyed. Patient RNA profiles are compared against a curated true-normal tissue database to statistically power diagnostic conclusions, and a curated drug-target-ligand database connects abnormally expressed genes to approved treatments and clinical trials. The company reports a diagnostic yield of close to 100% in matching patients to approved drugs, versus approximately 40% for DNA panels. The product surface has expanded with OneRNA® CDx AI, a companion diagnostics module that delivers an algorithm-based AI endpoint for pharma partners at a stated development cost of under $1M per program.

The company serves three customer segments: hospitals and healthcare systems (deploying OneRNA in their own CLIA labs with proprietary reagents, APIs, and HIPAA-compliant EMR integration under RNA-seq-specific payer codes); clinicians and oncologists (referring individual patient cases when standard treatment fails or cancer recurs); and pharmaceutical and biotech companies (target validation, companion diagnostics development, label expansion, and clinical study support, including rescue of failed drugs). Revenue mechanics span transaction-fee CLIA diagnostic testing, recurring hospital platform licensing, and professional services for pharma research and CDx development, with all pricing conducted on a quote-based, non-public basis. Distribution is direct and enterprise-led, with no channel or reseller model.

Genomic Expression is a privately held company headquartered in Beverly, Massachusetts, founded in 2009, with 1-10 employees. The company has raised approximately $6.5M cumulatively through grants from the Danish Innovation Fund, Horizon Europe, EuroStars, and the US National Cancer Institute, plus angel funding from Pipeline Angels and Harvard Business Angels, with additional disclosed rounds including a 2017 EISMEA grant and a 2018 financing. Management is led by CEO and co-founder Gitte Pedersen (former Novo Nordisk executive) alongside CSO Morten Pedersen and CMO Jesper Zeuthen (co-founder of GeneMap and Topotarget, both of which completed IPOs). The company is CLIA-validated, HIPAA-compliant, and has received recognition including Forbes feature, EIC Lifescience Award, MedTech Innovator Top 50, XTC Top 10, and XPRIZE Rapid Covid Testing semifinalist.

Genomic Expression firmographics

Firmographics
Name
Genomic Expression
Legal name
Genomic Expression
Website
https://genomicexpression.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Genomic Expression operates the OneRNA platform, a quantitative whole-transcriptome RNA sequencing system for cancer diagnostics that matches patients to approved drugs and clinical trials. It serves hospitals deploying the platform in-house, clinicians, and pharma companies developing companion diagnostics.
Ownership category
akta.pro rank

Genomic Expression industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • RNA sequencing diagnostics
  • Companion diagnostics services
  • Molecular diagnostics platform
  • Clinical laboratory testing
  • Transcriptome analysis services

Where Genomic Expression is headquartered

Location

Headquarters

HQ city
Beverly
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Genomic Expression business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. CLIA Diagnostic Testing Services: RNA-seq based cancer diagnostics performed in CLIA-certified lab, billed under RNA-seq-specific payer code. Revenue from diagnostic testing services matched to drugs and clinical trials.
  2. Hospital Platform Licensing: Hospitals implement OneRNA platform in their own CLIA labs using proprietary reagents and APIs, generating new revenue under RNA-seq payer codes.
  3. Pharma Research Services: Target validation, companion diagnostics development, and clinical study support services for biotech and pharma companies. CDx development under $1M with algorithm deliverables.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Genomic Expression product offering

Product offering

Core offering

Genomic Expression provides the OneRNA® Platform, a CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from real clinical samples (archival FFPE, CTCs, liquid biopsy) to detect disease and match oncology patients to approved drugs and clinical trials. The company commercializes this technology through three models: CLIA-certified diagnostic testing services reimbursed under RNA-seq-specific payer codes, licensing of the platform into hospital CLIA labs with proprietary reagents and APIs, and pharma research services for target validation, companion diagnostics development, and clinical study support.

Product overview

Genomic Expression offers a single unified platform, the OneRNA® Platform, augmented by a companion diagnostics module called OneRNA® CDx AI. The core OneRNA® Platform is a quantitative, CLIA-validated whole-transcriptome RNA-seq system that analyzes approximately 20,000 mRNAs from archival FFPE, CTCs, and liquid biopsy samples to match nearly all patients to approved drugs or clinical trials. The OneRNA® CDx AI module extends the platform by enabling pharmaceutical companies to derive companion diagnostics directly from whole-transcriptome data on an AI endpoint. Both offerings share the same underlying RNA-seq technology, sample types, and clinical validation infrastructure, with the CDx module representing a specialized application for drug development and label expansion.

Differentiator

Problem solved

Functional benefit

Brands

  • OneRNA®: A quantitative CLIA-validated whole-transcriptome RNA sequencing platform that analyzes all mRNAs to detect disease, match patients to drugs, and enable precision medicine in oncology.

Products and services

  • OneRNA® Platform Quantitative, CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from patient samples including archival FFPE, circulating tumor cells, and liquid biopsies (blood, saliva, urine) to detect disease, monitor health, and match cancer patients to approved drugs and clinical trials with close to 100% diagnostic yield. Compares patient RNA against a database of true normal tissue and connects abnormal gene expression to a curated drug-target-ligand database of approved treatments and clinical trials.
  • CLIA-Certified RNA Diagnostic Testing Services Diagnostic testing services performed in Genomic Expression's CLIA-certified laboratory using the OneRNA® Platform, billed under RNA-seq-specific payer codes and accepted by Medicare and select private payors. Delivers diagnostic reports matching patients to approved drugs and clinical trials.
  • OneRNA Platform Deployment for Hospital CLIA Labs Enterprise platform implementation service that installs the OneRNA® Platform in a hospital's own CLIA-certified laboratory, including proprietary reagents, APIs, and HIPAA-compliant EMR integration, enabling the hospital to run quantitative whole-transcriptome RNA diagnostics in-house and capture reimbursement under RNA-seq-specific payer codes.
  • Pharma RNA Research & Companion Diagnostics Services Research and development services for biotech and pharmaceutical partners, covering target validation using whole-transcriptome RNA, companion diagnostic (CDx) development with algorithm deliverables under $1M, clinical study design and support, label expansion, and rescue of failed drug programs using real patient RNA data.

Quantifiable outcome

  • Close to 100% diagnostic yield matching patients to approved drugs (vs 40% for DNA panels, dropping to 26% in low mutation tumors)
  • +3 more outcomes

Companies that use Genomic Expression

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Genomic Expression technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Genomic Expression partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Genomic Expression competitors and assessment

Company assessment

Broad incumbents

  • Foundation Medicine (Roche): Foundation Medicine is the dominant DNA-based comprehensive genomic profiling provider for oncology, serving hospitals, oncologists, and pharma CDx partners. It is comparable because it sells tumor profiling into the same hospital and pharma channels, but it is anchored on DNA panel content where Genomic Expression's whole-transcriptome approach claims superior yield.
  • Guardant Health: Guardant Health is a leading liquid-b biopsy and genomics company offering Guardant360 for tumor profiling and GuardantINFINITY for multi-omics including RNA. It is comparable because it serves oncology clinicians, hospitals, and pharma with tumor molecular profiling, with an increasing focus on RNA expression that overlaps with OneRNA's whole-transcriptome thesis.
  • Natera: Natera is a molecular diagnostics company offering cell-free DNA and RNA-based tests across oncology (Signatera for MRD) and reproductive health. It is comparable as a CLIA-certified molecular diagnostics operator with hospital and pharma channels, though anchored in cell-free DNA MRD rather than whole-transcriptome tumor profiling.
  • Tempus AI: Tempus is a large-scale AI-powered precision medicine company offering multi-modal sequencing (DNA and RNA), clinical data, and analytics for oncology. It is broadly comparable as an oncology sequencing and data platform targeting hospitals, clinicians, and pharma, but operates at far greater scale and with DNA-first workflows that Genomic Expression's RNA-first platform aims to differentiate against.
  • NeoGenomics: NeoGenomics is a clinical oncology laboratory offering comprehensive genomic profiling, including RNA fusion and expression assays, to hospitals and oncologists. It competes in the same hospital and CLIA diagnostic channel but with a much broader menu and footprint; relevant as an incumbent reference lab that Genomic Expression must displace or partner with.
  • Exact Sciences (Abbott): Exact Sciences, recently acquired by Abbott for ~$20B per company materials, is a major molecular diagnostics franchise with oncology screening and profiling products. It illustrates the size and M&A appetite for sequencing-based cancer diagnostics and is broadly comparable as a large-scale oncology molecular diagnostics operator.
  • Veracyte: Veracyte is a genomic diagnostics company offering RNA-based and multi-omics tests in oncology (e.g., Afirma for thyroid, Decipher Prostate). It is comparable as an RNA-first diagnostics operator serving hospitals and clinicians, but focused on specific indications rather than whole-transcriptome pan-oncology profiling.

Direct peers

  • Personalis: Personalis provides ImmunoID Next, a comprehensive tumor profiling platform combining whole-genome, exome, and RNA sequencing for oncology and immuno-oncology applications. Comparable as a direct competitor in whole-transcriptome tumor analysis serving pharma and clinical customers, with a similar emphasis on immune-therapy target and tumor microenvironment detection.
  • Caris Life Sciences: Caris offers multi-omics tumor profiling including whole-transcriptome RNA sequencing (MI Profile) plus DNA and protein analysis for oncology. It is the closest direct peer because it provides RNA-based molecular profiling and companion diagnostics to clinicians, hospitals, and pharma on a CLIA-certified basis, directly competing for the same diagnostic yield narrative.
  • Adaptive Biotechnologies: Adaptive Biotechnologies applies immune repertoire sequencing (T-cell and B-cell receptor sequencing via RNA) to oncology minimal residual disease and immune profiling. Comparable as an RNA-sequencing-driven diagnostics company serving pharma and clinicians, though focused on immune receptor rather than whole-transcriptome tumor profiling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Genomic Expression social profiles

Digital presence

Genomic Expression compliance and trust

Trust signal

Compliance2 records

Genomic Expression financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genomic Expression leadership team

Management profile

Number of profiles

Profiles3 records

Genomic Expression funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genomic Expression M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomic Expression

What does Genomic Expression do?

Genomic Expression provides the OneRNA® Platform, a CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from real clinical samples (archival FFPE, CTCs, liquid biopsy) to detect disease and match oncology patients to approved drugs and clinical trials. The company commercializes this technology through three models: CLIA-certified diagnostic testing services reimbursed under RNA-seq-specific payer codes, licensing of the platform into hospital CLIA labs with proprietary reagents and APIs, and pharma research services for target validation, companion diagnostics development, and clinical study support.

Is Genomic Expression a public or private company?

Genomic Expression is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Genomic Expression founded?

Genomic Expression was founded in 2009. It employs 11 to 50 people.

Where is Genomic Expression based?

Genomic Expression is headquartered in Beverly, United States, in the North America region.

How does Genomic Expression make money?

Three revenue lines are on record. CLIA Diagnostic Testing Services are the primary driver. The others are hospital Platform Licensing and pharma Research Services.

Who are Genomic Expression's main competitors?

Broad incumbents on record are Foundation Medicine (Roche), Guardant Health, Natera, Tempus AI, NeoGenomics, Exact Sciences (Abbott) and Veracyte. Direct peers are Personalis, Caris Life Sciences and Adaptive Biotechnologies.

Does Genomic Expression have an API?

No public API is recorded for Genomic Expression.

What industry is Genomic Expression in?

Genomic Expression's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGANAE, Transcriptomics & Gene Expression Profiling Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals